NASDAQ:TLRYTilray Stock Price, Forecast & News

Tilray's stock was trading at $7.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TLRY stock has increased by 6.8% and is now trading at $7.57. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 2 sell ratings, 12 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tilray.

Tilray is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Tilray.

Tilray Inc (NASDAQ:TLRY) issued its earnings results on Monday, May, 11th. The company reported ($1.73) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $1.29. The firm had revenue of $52.20 million for the quarter, compared to the consensus estimate of $49.37 million. Tilray had a negative return on equity of 62.82% and a negative net margin of 241.79%. The company's revenue was up 127.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.27) EPS. View Tilray's earnings history.

16 analysts have issued 1 year price objectives for Tilray's stock. Their forecasts range from $4.00 to $31.00. On average, they anticipate Tilray's stock price to reach $12.77 in the next twelve months. This suggests a possible upside of 68.7% from the stock's current price. View analysts' price targets for Tilray.

Media headlines about TLRY stock have trended somewhat negative recently, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Tilray earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Tilray.

Some companies that are related to Tilray include Cronos Group (CRON), USANA Health Sciences (USNA), Aphria (APHA), Aurora Cannabis (ACB), Canopy Rivers (RIV), Chromadex (CDXC), Mediwound (MDWD), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU), FitLife Brands (FTLF) and GLG Life Tech (GLGLF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Advanced Micro Devices (AMD), Aphria (APHA) and Square (SQ).

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Tilray's stock is owned by many different retail and institutional investors. Top institutional shareholders include Exane Derivatives (0.01%), AdvisorShares Investments LLC (0.01%) and Aua Capital Management LLC (0.01%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda and Michael Auerbach. View institutional ownership trends for Tilray.

TLRY stock was sold by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, and Michael Auerbach. View insider buying and selling activity for Tilray.

TLRY stock was bought by a variety of institutional investors in the last quarter, including Aua Capital Management LLC, and Exane Derivatives. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy, and Edward Wood Pastorius Jr. View insider buying and selling activity for Tilray.

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TLRY stock can currently be purchased for approximately $7.57.

Tilray has a market capitalization of $945.20 million and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Tilray employs 1,646 workers across the globe.

The official website for Tilray is www.tilray.com.

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.